Corporatization” of health care, a process predicted decades ago, now refers to the general trend throughout the industry toward higher levels of integrated control by consolidated profit-seeking ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the ...

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

One of the more difficult decisions for patients with poorly controlled type 2 diabetes, as well as for their clinicians, is ...

From 2009 through 2024, a total of 889 patients underwent randomization to the exercise group (445 patients) or the health-education group (444 patients).

A total of 278 patients were randomly assigned to the tenecteplase–thrombectomy group and 272 to the thrombectomy-alone group. Functional independence at 90 days was observed in 147 patients (52 ...

This article from the FDA compares broad U.S. recommendations on Covid vaccination with those from other countries and announces the adoption of an evidence-based approach to such recommendations.

A total of 2516 participants underwent randomization; 1797 (71.4%) completed the trial. Of 2421 participants in the full analysis population (1209 assigned to the albuterol–budesonide group and ...

Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B (PDE4B). In preclinical models of lung fibrosis, nerandomilast showed antifibrotic and ...

VERITAS was an investigator-initiated, multicenter, open-label, randomized, parallel-group, noninferiority trial in which navigational bronchoscopy was compared with transthoracic needle biopsy in ...

Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with idiopa ...

Audio Interview from the New England Journal of Medicine — Interview with Alice Chen on responding to the U.S. administration’s threats to health and physicians’ values and maintaining hope ...